Companion Diagnostics for Oncology Market By Offering (Assay Kits & Reagents, Software, Services), By Technology (In Situ Hybridization (ISH), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Others), By Disease Indication (Breast Cancer, Ovarian Cancer, Colorectal cancer, Non-small Cell Lung Cancer, Blood Cancer, Others), By End Users (Hospitals, Diagnostics Laboratories, Others), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Companion diagnostic, or CDx, for oncology guides the use of personalized therapy options for advanced cancer patients by identifying FDA-approved treatment alternatives that may be appropriate depending on the unique drivers of the cancer. A test assists in matching a patient to a certain medicine or therapy. A companion diagnostic test, for example, may determine whether a patient's tumor has a specific gene alteration or biomarker that is targeted by the medicine. Companion diagnostic tests are currently used for a variety of cancers to aid in the identification of specific genetic/somatic alterations in patient samples that are targets for targeted therapy. With the fast growth of precision medicine and more than half of pipeline medicines expected to eventually have an associated biomarker, there seems to be positive growth prospects for companion diagnostics for oncology market over the projection period.
The increasing need for personalized medication, discovery of improved biomarkers for various illnesses, and expanding unmet medical requirements are significant drivers of companion diagnostics for oncology market. Major players are also contributing towards the market growth by undertaking investments for developments. Genetron Holdings Limited, for instance, a precision oncology platform company in China, and its strategic partner CStone Pharmaceuticals announced the launch of a multi-center clinical trial in China for the joint development of an avapritinib companion diagnostic (CDx) test in September 2020. Genetron Health and CStone are working together to create a CDx kit that will use polymerase chain reaction (PCR) to detect the D842V mutation in the human platelet-derived growth factor receptor alpha (PDGFRA) gene. The test has been validated by the National Medical Products Administration's (NMPA) testing lab and is now being used in this multi-center clinical trial in China.
The COVID-19 pandemic had affected around 192 million people globally as of July 22, 2021, resulting in 4.13 million deaths. Governments declared strict lockdowns across various countries to limit the likelihood of spreading the infection. While this condition mostly affects the lungs, causing pneumonia and acute respiratory distress syndrome, it also has a deleterious impact on cancer care. The impact of the COVID-19 pandemic on cancer care in the United States has resulted in declines and delays in recognizing new cancers and delivering treatment in the first half of 2020. However, with the recovery of covid-19 illnesses, key players and the government are now focused on other chronic diseases. Moreover, the increased promise of innovation in companion diagnostics tests will in the near future provide new opportunities for the growth of companion diagnostics for oncology market participants in the healthcare sector.
In terms of revenue, companion diagnostics for oncology market was valued at US$ 2762.68 Mn in 2021 growing at a CAGR of 12.9% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Companion Diagnostics for Oncology Market Revenue & Forecast, (US$ Million), 2015 – 2030
Offering Outlook:
Based on offering, the global companion diagnostics for oncology market has been primarily segmented into assay kits & reagents, software, and services. Assay kits and reagents accounted for a sizable market share and are predicted to expand throughout the forecast period. The expanding worldwide cancer burden, as well as the emergence of new technologies such as NGS for cancer diagnostics, are major factors driving product revenue growth in the global market.
Technology Outlook:
Based on technology, the global companion diagnostics for oncology market has been segmented into in situ hybridization (ISH), polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and others. In situ hybridization (ISH) held the largest market share in 2021. In situ hybridization is a laboratory method that allows a single-stranded DNA or RNA sequence known as a probe to generate complementary base pairs with DNA or RNA found in a tissue or chromosomal sample. Furthermore, continual development in the healthcare industry is another major factor driving the segment’s growth.
Disease Indication Outlook:
Based on disease indication, the global companion diagnostics for oncology market has been segmented into breast cancer, ovarian cancer, colorectal cancer, non-small cell lung cancer, blood cancer, and others. Breast cancer is predicted to grow significantly during the forecast period, owing to an increase in the global incidence of breast cancer, development of companion diagnostic solutions, and a favorable reimbursement landscape. According to the world health organization, in 2020, there were 2.3 million new cases of breast cancer and 685 000 deaths worldwide. By the end of 2020, 7.8 million women had been diagnosed with breast cancer in the previous five years, making it the world's most common cancer.
End Users Outlook:
Based on end-users, the global companion diagnostics for oncology market has been segmented into hospitals, diagnostics laboratories, and others. The hospital’s segment accounted for the highest share of the market in 2021. Increasing implementation of companion diagnostics for cancer in hospitals to manage a large number of patient pools has contributed towards the segment’s high share in the global market. Furthermore, developments in cancer diagnosis and treatment, as well as the accessibility of competent specialists across hospitals is an essential factor aiding the segment’s sustained growth in the market.
Region Outlook:
North America accounted for the largest share in the global companion diagnostics for oncology market in 2021 owing to significant increase in FDA approval of the companion diagnostics products for oncology. Medical device manufacturers continue to spend in diagnostics device R&D, resulting in continuous advancements in medical technology. Some of the companies in the region are aiding the market expansion by introducing new products in the market. For instance, Labcorp, a global life sciences company, announced the release of therascreen KRAS PCR Mutation Analysis in July 2021. It is a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for diagnosis with LUMAKRAS (sotorasib), an Amgen-developed new treatment option. In late May 2021, the U.S. Food and Drug Administration (FDA) approved the therapy and thus indicated usage of the test as a companion diagnostic.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of companion diagnostics for oncology market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the players operating in the global companion diagnostics for oncology market are:
- Abbott Laboratories
- Amgen Inc.
- ARUP Laboratories, Inc.
- AstraZeneca
- bioMérieux Inc.
- Hoffmann-La Roche Ltd
- FOUNDATION MEDICINE, INC.
- Guardant Health, Inc.
- ICON plc
- Illumina, Inc.
- Invivoscribe Technologies, Inc.
- Leica Biosystems
- Myriad Genetics, Inc.
- Pillar Biosciences, Inc.
- Resonance Health Analysis Services Pty Ltd
- Thermo Fisher Scientific Inc.
- Other Market Participants
Global Companion Diagnostics for Oncology Market:
- By Offering
- Assay Kits & Reagents
- Software
- Services
- By Technology
- In Situ Hybridization (ISH)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Next-Generation Sequencing (NGS)
- Others
- By Disease Indication
- Breast Cancer
- Ovarian Cancer
- Colorectal cancer
- Non-small Cell Lung Cancer
- Blood Cancer
- Others
- By End Users
- Hospitals
- Diagnostics Laboratories
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2021
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Companion Diagnostics for Oncology
Market
6. Market Synopsis:
Companion Diagnostics for Oncology Market
7. Companion Diagnostics for Oncology Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Companion Diagnostics for Oncology Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Companion Diagnostics for Oncology Market
7.6. Porter’s
Five Force Analysis
8. Global Companion Diagnostics for Oncology Market Analysis and
Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global
Companion Diagnostics for Oncology Market Revenue (US$ Mn)
8.2. Global
Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts, By Offering
8.2.1. Assay
Kits and Reagents
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2021
8.2.1.3. Market Forecast, 2022 - 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2021
8.2.1.5.1.2. Market
Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2021
8.2.1.5.2.2. Market
Forecast, 2022 - 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2021
8.2.1.5.3.2. Market
Forecast, 2022 - 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2021
8.2.1.5.4.2. Market
Forecast, 2022 - 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2021
8.2.1.5.5.2. Market
Forecast, 2022 - 2030
8.2.2. Software
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 - 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.2.3. Services
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2021
8.2.3.3. Market Forecast, 2022 - 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2021
8.2.3.5.1.2. Market
Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2021
8.2.3.5.2.2. Market
Forecast, 2022 - 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2021
8.2.3.5.3.2. Market
Forecast, 2022 - 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2021
8.2.3.5.4.2. Market
Forecast, 2022 - 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2021
8.2.3.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By
Offering
9. Global Companion Diagnostics for Oncology Market Analysis and
Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts, By
Technology
9.2.1. In Situ
Hybridization (ISH)
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Polymerase
Chain Reaction (PCR)
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.2.3. Immunohistochemistry
(IHC)
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2021
9.2.3.3. Market Forecast, 2022 - 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2021
9.2.3.5.1.2. Market
Forecast, 2022 - 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2021
9.2.3.5.2.2. Market
Forecast, 2022 - 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2021
9.2.3.5.3.2. Market
Forecast, 2022 - 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2021
9.2.3.5.4.2. Market
Forecast, 2022 - 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2021
9.2.3.5.5.2. Market
Forecast, 2022 - 2030
9.2.4. Next-Generation
Sequencing (NGS)
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 - 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2021
9.2.4.5.1.2. Market
Forecast, 2022 - 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2021
9.2.4.5.2.2. Market
Forecast, 2022 - 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2021
9.2.4.5.3.2. Market
Forecast, 2022 - 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2021
9.2.4.5.4.2. Market
Forecast, 2022 - 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2021
9.2.4.5.5.2. Market
Forecast, 2022 - 2030
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 - 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2021
9.2.5.5.1.2. Market
Forecast, 2022 - 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2021
9.2.5.5.2.2. Market
Forecast, 2022 - 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2021
9.2.5.5.3.2. Market
Forecast, 2022 - 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2021
9.2.5.5.4.2. Market
Forecast, 2022 - 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2021
9.2.5.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Technology
10. Global Companion Diagnostics for Oncology Market Analysis and
Forecasts, 2022 – 2030
10.1. Overview
10.2. Global
Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
10.2.1. Breast
Cancer
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Ovarian
Cancer
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.2.3. Colorectal
cancer
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 - 2030
10.2.4. Non-small
Cell Lung Cancer
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2021
10.2.4.3. Market Forecast, 2022 - 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 - 2030
10.2.5. Blood
Cancer
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2021
10.2.5.3. Market Forecast, 2022 - 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 - 2021
10.2.5.5.1.2. Market
Forecast, 2022 - 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2021
10.2.5.5.2.2. Market
Forecast, 2022 - 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2021
10.2.5.5.3.2. Market
Forecast, 2022 - 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2021
10.2.5.5.4.2. Market
Forecast, 2022 - 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 - 2021
10.2.5.5.5.2. Market
Forecast, 2022 - 2030
10.2.6. Others
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 - 2021
10.2.6.3. Market Forecast, 2022 - 2030
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market
Estimation, 2015 - 2021
10.2.6.5.1.2. Market
Forecast, 2022 - 2030
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 - 2021
10.2.6.5.2.2. Market
Forecast, 2022 - 2030
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market
Estimation, 2015 - 2021
10.2.6.5.3.2. Market
Forecast, 2022 - 2030
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 - 2021
10.2.6.5.4.2. Market
Forecast, 2022 - 2030
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market
Estimation, 2015 - 2021
10.2.6.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By
Disease Indication
11. Global Companion Diagnostics for Oncology Market Analysis and
Forecasts, 2022 – 2030
11.1. Overview
11.2. Global
Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts, By
End Users
11.2.1. Hospitals
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2021
11.2.1.3. Market Forecast, 2022 - 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2021
11.2.1.5.1.2. Market
Forecast, 2022 - 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2021
11.2.1.5.2.2. Market
Forecast, 2022 - 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2021
11.2.1.5.3.2. Market
Forecast, 2022 - 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2021
11.2.1.5.4.2. Market
Forecast, 2022 - 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2021
11.2.1.5.5.2. Market
Forecast, 2022 - 2030
11.2.2. Diagnostics
Laboratories
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2021
11.2.2.3. Market Forecast, 2022 - 2030
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2021
11.2.2.5.1.2. Market
Forecast, 2022 - 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2021
11.2.2.5.2.2. Market
Forecast, 2022 - 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2021
11.2.2.5.3.2. Market
Forecast, 2022 - 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2021
11.2.2.5.4.2. Market
Forecast, 2022 - 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2021
11.2.2.5.5.2. Market
Forecast, 2022 - 2030
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2021
11.2.3.3. Market Forecast, 2022 - 2030
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2021
11.2.3.5.1.2. Market
Forecast, 2022 - 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2021
11.2.3.5.2.2. Market
Forecast, 2022 - 2030
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2021
11.2.3.5.3.2. Market
Forecast, 2022 - 2030
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2021
11.2.3.5.4.2. Market
Forecast, 2022 - 2030
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2021
11.2.3.5.5.2. Market
Forecast, 2022 - 2030
11.3. Key
Segment for Channeling Investments
11.3.1. By End
Users
12. North America Companion Diagnostics for Oncology Market
Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. North
America Companion Diagnostics for Oncology Market Revenue (US$ Mn)
12.2. North
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Offering
12.2.1. Assay
Kits and Reagents
12.2.2. Software
12.2.3. Services
12.3. North
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Technology
12.3.1. In Situ
Hybridization (ISH)
12.3.2. Polymerase
Chain Reaction (PCR)
12.3.3. Immunohistochemistry
(IHC)
12.3.4. Next-Generation
Sequencing (NGS)
12.3.5. Others
12.4. North
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
12.4.1. Breast
Cancer
12.4.2. Ovarian
Cancer
12.4.3. Colorectal
cancer
12.4.4. Non-small
Cell Lung Cancer
12.4.5. Blood
Cancer
12.4.6. Others
12.5. North
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.1. Hospitals
12.5.2. Diagnostics
Laboratories
12.5.3. Others
12.6. North
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Companion Diagnostics for Oncology Market Revenue (US$ Mn)
and Forecasts, By Offering
12.6.1.1.1. Assay Kits and Reagents
12.6.1.1.2. Software
12.6.1.1.3. Services
12.6.1.2. U.S Companion Diagnostics for Oncology Market Revenue (US$ Mn)
and Forecasts, By Technology
12.6.1.2.1. In Situ Hybridization (ISH)
12.6.1.2.2. Polymerase Chain Reaction (PCR)
12.6.1.2.3. Immunohistochemistry (IHC)
12.6.1.2.4. Next-Generation Sequencing (NGS)
12.6.1.2.5. Others
12.6.1.3. U.S Companion Diagnostics for Oncology Market Revenue (US$ Mn)
and Forecasts, By Disease Indication
12.6.1.3.1. Breast Cancer
12.6.1.3.2. Ovarian Cancer
12.6.1.3.3. Colorectal cancer
12.6.1.3.4. Non-small Cell Lung Cancer
12.6.1.3.5. Blood Cancer
12.6.1.3.6. Others
12.6.1.4. U.S Companion Diagnostics for Oncology Market Revenue (US$ Mn)
and Forecasts, By End Users
12.6.1.4.1. Hospitals
12.6.1.4.2. Diagnostics Laboratories
12.6.1.4.3. Others
12.6.2. Canada
12.6.2.1. Canada Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
12.6.2.1.1. Assay Kits and Reagents
12.6.2.1.2. Software
12.6.2.1.3. Services
12.6.2.2. Canada Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
12.6.2.2.1. In Situ Hybridization (ISH)
12.6.2.2.2. Polymerase Chain Reaction (PCR)
12.6.2.2.3. Immunohistochemistry (IHC)
12.6.2.2.4. Next-Generation Sequencing (NGS)
12.6.2.2.5. Others
12.6.2.3. Canada Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
12.6.2.3.1. Breast Cancer
12.6.2.3.2. Ovarian Cancer
12.6.2.3.3. Colorectal cancer
12.6.2.3.4. Non-small Cell Lung Cancer
12.6.2.3.5. Blood Cancer
12.6.2.3.6. Others
12.6.2.4. Canada Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.2.4.1. Hospitals
12.6.2.4.2. Diagnostics Laboratories
12.6.2.4.3. Others
12.6.3. Mexico
12.6.3.1. Mexico Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
12.6.3.1.1. Assay Kits and Reagents
12.6.3.1.2. Software
12.6.3.1.3. Services
12.6.3.2. Mexico Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
12.6.3.2.1. In Situ Hybridization (ISH)
12.6.3.2.2. Polymerase Chain Reaction (PCR)
12.6.3.2.3. Immunohistochemistry (IHC)
12.6.3.2.4. Next-Generation Sequencing (NGS)
12.6.3.2.5. Others
12.6.3.3. Mexico Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
12.6.3.3.1. Breast Cancer
12.6.3.3.2. Ovarian Cancer
12.6.3.3.3. Colorectal cancer
12.6.3.3.4. Non-small Cell Lung Cancer
12.6.3.3.5. Blood Cancer
12.6.3.3.6. Others
12.6.3.4. Mexico Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.3.4.1. Hospitals
12.6.3.4.2. Diagnostics Laboratories
12.6.3.4.3. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Companion Diagnostics for Oncology
Market Revenue (US$ Mn) and Forecasts, By Offering
12.6.4.1.1. Assay Kits and Reagents
12.6.4.1.2. Software
12.6.4.1.3. Services
12.6.4.2. Rest of North America Companion Diagnostics for Oncology
Market Revenue (US$ Mn) and Forecasts, By Technology
12.6.4.2.1. In Situ Hybridization (ISH)
12.6.4.2.2. Polymerase Chain Reaction (PCR)
12.6.4.2.3. Immunohistochemistry (IHC)
12.6.4.2.4. Next-Generation Sequencing (NGS)
12.6.4.2.5. Others
12.6.4.3. Rest of North America Companion Diagnostics for Oncology
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.6.4.3.1. Breast Cancer
12.6.4.3.2. Ovarian Cancer
12.6.4.3.3. Colorectal cancer
12.6.4.3.4. Non-small Cell Lung Cancer
12.6.4.3.5. Blood Cancer
12.6.4.3.6. Others
12.6.4.4. Rest of North America Companion Diagnostics for Oncology
Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1. Hospitals
12.6.4.4.2. Diagnostics Laboratories
12.6.4.4.3. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Offering
12.7.3. By
Technology
12.7.4. By
Disease Indication
12.7.5. By End
Users
13. Europe Companion Diagnostics for Oncology Market Analysis and
Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Europe
Companion Diagnostics for Oncology Market Revenue (US$ Mn)
13.2. Europe
Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts, By
Offering
13.2.1. Assay
Kits and Reagents
13.2.2. Software
13.2.3. Services
13.3. Europe
Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts, By
Technology
13.3.1. In Situ
Hybridization (ISH)
13.3.2. Polymerase
Chain Reaction (PCR)
13.3.3. Immunohistochemistry
(IHC)
13.3.4. Next-Generation
Sequencing (NGS)
13.3.5. Others
13.4. Europe
Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
13.4.1. Breast
Cancer
13.4.2. Ovarian
Cancer
13.4.3. Colorectal
cancer
13.4.4. Non-small
Cell Lung Cancer
13.4.5. Blood
Cancer
13.4.6. Others
13.5. Europe
Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts, By
End Users
13.5.1. Hospitals
13.5.2. Diagnostics
Laboratories
13.5.3. Others
13.6. Europe
Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.1. France
13.6.1.1. France Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
13.6.1.1.1. Assay Kits and Reagents
13.6.1.1.2. Software
13.6.1.1.3. Services
13.6.1.2. France Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
13.6.1.2.1. In Situ Hybridization (ISH)
13.6.1.2.2. Polymerase Chain Reaction (PCR)
13.6.1.2.3. Immunohistochemistry (IHC)
13.6.1.2.4. Next-Generation Sequencing (NGS)
13.6.1.2.5. Others
13.6.1.3. France Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
13.6.1.3.1. Breast Cancer
13.6.1.3.2. Ovarian Cancer
13.6.1.3.3. Colorectal cancer
13.6.1.3.4. Non-small Cell Lung Cancer
13.6.1.3.5. Blood Cancer
13.6.1.3.6. Others
13.6.1.4. France Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.1.4.1. Hospitals
13.6.1.4.2. Diagnostics Laboratories
13.6.1.4.3. Others
13.6.2. The UK
13.6.2.1. The UK Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
13.6.2.1.1. Assay Kits and Reagents
13.6.2.1.2. Software
13.6.2.1.3. Services
13.6.2.2. The UK Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
13.6.2.2.1. In Situ Hybridization (ISH)
13.6.2.2.2. Polymerase Chain Reaction (PCR)
13.6.2.2.3. Immunohistochemistry (IHC)
13.6.2.2.4. Next-Generation Sequencing (NGS)
13.6.2.2.5. Others
13.6.2.3. The UK Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
13.6.2.3.1. Breast Cancer
13.6.2.3.2. Ovarian Cancer
13.6.2.3.3. Colorectal cancer
13.6.2.3.4. Non-small Cell Lung Cancer
13.6.2.3.5. Blood Cancer
13.6.2.3.6. Others
13.6.2.4. The UK Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.2.4.1. Hospitals
13.6.2.4.2. Diagnostics Laboratories
13.6.2.4.3. Others
13.6.3. Spain
13.6.3.1. Spain Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
13.6.3.1.1. Assay Kits and Reagents
13.6.3.1.2. Software
13.6.3.1.3. Services
13.6.3.2. Spain Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
13.6.3.2.1. In Situ Hybridization (ISH)
13.6.3.2.2. Polymerase Chain Reaction (PCR)
13.6.3.2.3. Immunohistochemistry (IHC)
13.6.3.2.4. Next-Generation Sequencing (NGS)
13.6.3.2.5. Others
13.6.3.3. Spain Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
13.6.3.3.1. Breast Cancer
13.6.3.3.2. Ovarian Cancer
13.6.3.3.3. Colorectal cancer
13.6.3.3.4. Non-small Cell Lung Cancer
13.6.3.3.5. Blood Cancer
13.6.3.3.6. Others
13.6.3.4. Spain Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.3.4.1. Hospitals
13.6.3.4.2. Diagnostics Laboratories
13.6.3.4.3. Others
13.6.4. Germany
13.6.4.1. Germany Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
13.6.4.1.1. Assay Kits and Reagents
13.6.4.1.2. Software
13.6.4.1.3. Services
13.6.4.2. Germany Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
13.6.4.2.1. In Situ Hybridization (ISH)
13.6.4.2.2. Polymerase Chain Reaction (PCR)
13.6.4.2.3. Immunohistochemistry (IHC)
13.6.4.2.4. Next-Generation Sequencing (NGS)
13.6.4.2.5. Others
13.6.4.3. Germany Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
13.6.4.3.1. Breast Cancer
13.6.4.3.2. Ovarian Cancer
13.6.4.3.3. Colorectal cancer
13.6.4.3.4. Non-small Cell Lung Cancer
13.6.4.3.5. Blood Cancer
13.6.4.3.6. Others
13.6.4.4. Germany Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.4.4.1. Hospitals
13.6.4.4.2. Diagnostics Laboratories
13.6.4.4.3. Others
13.6.5. Italy
13.6.5.1. Italy Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
13.6.5.1.1. Assay Kits and Reagents
13.6.5.1.2. Software
13.6.5.1.3. Services
13.6.5.2. Italy Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
13.6.5.2.1. In Situ Hybridization (ISH)
13.6.5.2.2. Polymerase Chain Reaction (PCR)
13.6.5.2.3. Immunohistochemistry (IHC)
13.6.5.2.4. Next-Generation Sequencing (NGS)
13.6.5.2.5. Others
13.6.5.3. Italy Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
13.6.5.3.1. Breast Cancer
13.6.5.3.2. Ovarian Cancer
13.6.5.3.3. Colorectal cancer
13.6.5.3.4. Non-small Cell Lung Cancer
13.6.5.3.5. Blood Cancer
13.6.5.3.6. Others
13.6.5.4. Italy Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.5.4.1. Hospitals
13.6.5.4.2. Diagnostics Laboratories
13.6.5.4.3. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Offering
13.6.6.1.1. Assay Kits and Reagents
13.6.6.1.2. Software
13.6.6.1.3. Services
13.6.6.2. Nordic Countries Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Technology
13.6.6.2.1. In Situ Hybridization (ISH)
13.6.6.2.2. Polymerase Chain Reaction (PCR)
13.6.6.2.3. Immunohistochemistry (IHC)
13.6.6.2.4. Next-Generation Sequencing (NGS)
13.6.6.2.5. Others
13.6.6.3. Nordic Countries Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
13.6.6.3.1. Breast Cancer
13.6.6.3.2. Ovarian Cancer
13.6.6.3.3. Colorectal cancer
13.6.6.3.4. Non-small Cell Lung Cancer
13.6.6.3.5. Blood Cancer
13.6.6.3.6. Others
13.6.6.4. Nordic Countries Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1. Hospitals
13.6.6.4.2. Diagnostics Laboratories
13.6.6.4.3. Others
13.6.6.5. Nordic Countries Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Offering
13.6.7.1.1. Assay Kits and Reagents
13.6.7.1.2. Software
13.6.7.1.3. Services
13.6.7.2. Benelux Union Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Technology
13.6.7.2.1. In Situ Hybridization (ISH)
13.6.7.2.2. Polymerase Chain Reaction (PCR)
13.6.7.2.3. Immunohistochemistry (IHC)
13.6.7.2.4. Next-Generation Sequencing (NGS)
13.6.7.2.5. Others
13.6.7.3. Benelux Union Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
13.6.7.3.1. Breast Cancer
13.6.7.3.2. Ovarian Cancer
13.6.7.3.3. Colorectal cancer
13.6.7.3.4. Non-small Cell Lung Cancer
13.6.7.3.5. Blood Cancer
13.6.7.3.6. Others
13.6.7.4. Benelux Union Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.7.4.1. Hospitals
13.6.7.4.2. Diagnostics Laboratories
13.6.7.4.3. Others
13.6.7.5. Benelux Union Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Offering
13.6.8.1.1. Assay Kits and Reagents
13.6.8.1.2. Software
13.6.8.1.3. Services
13.6.8.2. Rest of Europe Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Technology
13.6.8.2.1. In Situ Hybridization (ISH)
13.6.8.2.2. Polymerase Chain Reaction (PCR)
13.6.8.2.3. Immunohistochemistry (IHC)
13.6.8.2.4. Next-Generation Sequencing (NGS)
13.6.8.2.5. Others
13.6.8.3. Rest of Europe Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
13.6.8.3.1. Breast Cancer
13.6.8.3.2. Ovarian Cancer
13.6.8.3.3. Colorectal cancer
13.6.8.3.4. Non-small Cell Lung Cancer
13.6.8.3.5. Blood Cancer
13.6.8.3.6. Others
13.6.8.4. Rest of Europe Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.4.1. Hospitals
13.6.8.4.2. Diagnostics Laboratories
13.6.8.4.3. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By Country
13.7.2. By
Offering
13.7.3. By
Technology
13.7.4. By
Disease Indication
13.7.5. By End
Users
14. Asia Pacific Companion Diagnostics for Oncology Market
Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Asia
Pacific Companion Diagnostics for Oncology Market Revenue (US$ Mn)
14.2. Asia
Pacific Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Offering
14.2.1. Assay
Kits and Reagents
14.2.2. Software
14.2.3. Services
14.3. Asia
Pacific Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Technology
14.3.1. In Situ
Hybridization (ISH)
14.3.2. Polymerase
Chain Reaction (PCR)
14.3.3. Immunohistochemistry
(IHC)
14.3.4. Next-Generation
Sequencing (NGS)
14.3.5. Others
14.4. Asia
Pacific Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
14.4.1. Breast
Cancer
14.4.2. Ovarian
Cancer
14.4.3. Colorectal
cancer
14.4.4. Non-small
Cell Lung Cancer
14.4.5. Blood
Cancer
14.4.6. Others
14.5. Asia
Pacific Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By End Users
14.5.1. Hospitals
14.5.2. Diagnostics
Laboratories
14.5.3. Others
14.6. Asia
Pacific Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.1. China
14.6.1.1. China Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
14.6.1.1.1. Assay Kits and Reagents
14.6.1.1.2. Software
14.6.1.1.3. Services
14.6.1.2. China Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
14.6.1.2.1. In Situ Hybridization (ISH)
14.6.1.2.2. Polymerase Chain Reaction (PCR)
14.6.1.2.3. Immunohistochemistry (IHC)
14.6.1.2.4. Next-Generation Sequencing (NGS)
14.6.1.2.5. Others
14.6.1.3. China Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
14.6.1.3.1. Breast Cancer
14.6.1.3.2. Ovarian Cancer
14.6.1.3.3. Colorectal cancer
14.6.1.3.4. Non-small Cell Lung Cancer
14.6.1.3.5. Blood Cancer
14.6.1.3.6. Others
14.6.1.4. China Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.1.4.1. Hospitals
14.6.1.4.2. Diagnostics Laboratories
14.6.1.4.3. Others
14.6.2. Japan
14.6.2.1. Japan Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
14.6.2.1.1. Assay Kits and Reagents
14.6.2.1.2. Software
14.6.2.1.3. Services
14.6.2.2. Japan Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
14.6.2.2.1. In Situ Hybridization (ISH)
14.6.2.2.2. Polymerase Chain Reaction (PCR)
14.6.2.2.3. Immunohistochemistry (IHC)
14.6.2.2.4. Next-Generation Sequencing (NGS)
14.6.2.2.5. Others
14.6.2.3. Japan Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
14.6.2.3.1. Breast Cancer
14.6.2.3.2. Ovarian Cancer
14.6.2.3.3. Colorectal cancer
14.6.2.3.4. Non-small Cell Lung Cancer
14.6.2.3.5. Blood Cancer
14.6.2.3.6. Others
14.6.2.4. Japan Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.2.4.1. Hospitals
14.6.2.4.2. Diagnostics Laboratories
14.6.2.4.3. Others
14.6.3. India
14.6.3.1. India Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
14.6.3.1.1. Assay Kits and Reagents
14.6.3.1.2. Software
14.6.3.1.3. Services
14.6.3.2. India Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
14.6.3.2.1. In Situ Hybridization (ISH)
14.6.3.2.2. Polymerase Chain Reaction (PCR)
14.6.3.2.3. Immunohistochemistry (IHC)
14.6.3.2.4. Next-Generation Sequencing (NGS)
14.6.3.2.5. Others
14.6.3.3. India Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
14.6.3.3.1. Breast Cancer
14.6.3.3.2. Ovarian Cancer
14.6.3.3.3. Colorectal cancer
14.6.3.3.4. Non-small Cell Lung Cancer
14.6.3.3.5. Blood Cancer
14.6.3.3.6. Others
14.6.3.4. India Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.3.4.1. Hospitals
14.6.3.4.2. Diagnostics Laboratories
14.6.3.4.3. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Offering
14.6.4.1.1. Assay Kits and Reagents
14.6.4.1.2. Software
14.6.4.1.3. Services
14.6.4.2. New Zealand Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Technology
14.6.4.2.1. In Situ Hybridization (ISH)
14.6.4.2.2. Polymerase Chain Reaction (PCR)
14.6.4.2.3. Immunohistochemistry (IHC)
14.6.4.2.4. Next-Generation Sequencing (NGS)
14.6.4.2.5. Others
14.6.4.3. New Zealand Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
14.6.4.3.1. Breast Cancer
14.6.4.3.2. Ovarian Cancer
14.6.4.3.3. Colorectal cancer
14.6.4.3.4. Non-small Cell Lung Cancer
14.6.4.3.5. Blood Cancer
14.6.4.3.6. Others
14.6.4.4. New Zealand Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.4.4.1. Hospitals
14.6.4.4.2. Diagnostics Laboratories
14.6.4.4.3. Others
14.6.5. Australia
14.6.5.1. Australia Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Offering
14.6.5.1.1. Assay Kits and Reagents
14.6.5.1.2. Software
14.6.5.1.3. Services
14.6.5.2. Australia Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Technology
14.6.5.2.1. In Situ Hybridization (ISH)
14.6.5.2.2. Polymerase Chain Reaction (PCR)
14.6.5.2.3. Immunohistochemistry (IHC)
14.6.5.2.4. Next-Generation Sequencing (NGS)
14.6.5.2.5. Others
14.6.5.3. Australia Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
14.6.5.3.1. Breast Cancer
14.6.5.3.2. Ovarian Cancer
14.6.5.3.3. Colorectal cancer
14.6.5.3.4. Non-small Cell Lung Cancer
14.6.5.3.5. Blood Cancer
14.6.5.3.6. Others
14.6.5.4. Australia Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.5.4.1. Hospitals
14.6.5.4.2. Diagnostics Laboratories
14.6.5.4.3. Others
14.6.6. South
Korea
14.6.6.1. South Korea Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Offering
14.6.6.1.1. Assay Kits and Reagents
14.6.6.1.2. Software
14.6.6.1.3. Services
14.6.6.2. South Korea Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Technology
14.6.6.2.1. In Situ Hybridization (ISH)
14.6.6.2.2. Polymerase Chain Reaction (PCR)
14.6.6.2.3. Immunohistochemistry (IHC)
14.6.6.2.4. Next-Generation Sequencing (NGS)
14.6.6.2.5. Others
14.6.6.3. South Korea Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
14.6.6.3.1. Breast Cancer
14.6.6.3.2. Ovarian Cancer
14.6.6.3.3. Colorectal cancer
14.6.6.3.4. Non-small Cell Lung Cancer
14.6.6.3.5. Blood Cancer
14.6.6.3.6. Others
14.6.6.4. South Korea Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.6.4.1. Hospitals
14.6.6.4.2. Diagnostics Laboratories
14.6.6.4.3. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Offering
14.6.7.1.1. Assay Kits and Reagents
14.6.7.1.2. Software
14.6.7.1.3. Services
14.6.7.2. Southeast Asia Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Technology
14.6.7.2.1. In Situ Hybridization (ISH)
14.6.7.2.2. Polymerase Chain Reaction (PCR)
14.6.7.2.3. Immunohistochemistry (IHC)
14.6.7.2.4. Next-Generation Sequencing (NGS)
14.6.7.2.5. Others
14.6.7.3. Southeast Asia Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
14.6.7.3.1. Breast Cancer
14.6.7.3.2. Ovarian Cancer
14.6.7.3.3. Colorectal cancer
14.6.7.3.4. Non-small Cell Lung Cancer
14.6.7.3.5. Blood Cancer
14.6.7.3.6. Others
14.6.7.4. Southeast Asia Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.7.4.1. Hospitals
14.6.7.4.2. Diagnostics Laboratories
14.6.7.4.3. Others
14.6.7.5. Southeast Asia Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Offering
14.6.8.1.1. Assay Kits and Reagents
14.6.8.1.2. Software
14.6.8.1.3. Services
14.6.8.2. Rest of Asia Pacific Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Technology
14.6.8.2.1. In Situ Hybridization (ISH)
14.6.8.2.2. Polymerase Chain Reaction (PCR)
14.6.8.2.3. Immunohistochemistry (IHC)
14.6.8.2.4. Next-Generation Sequencing (NGS)
14.6.8.2.5. Others
14.6.8.3. Rest of Asia Pacific Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
14.6.8.3.1. Breast Cancer
14.6.8.3.2. Ovarian Cancer
14.6.8.3.3. Colorectal cancer
14.6.8.3.4. Non-small Cell Lung Cancer
14.6.8.3.5. Blood Cancer
14.6.8.3.6. Others
14.6.8.4. Rest of Asia Pacific Companion Diagnostics for Oncology Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1. Hospitals
14.6.8.4.2. Diagnostics Laboratories
14.6.8.4.3. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Offering
14.7.3. By
Technology
14.7.4. By
Disease Indication
14.7.5. By End
Users
15. Middle East and Africa Companion Diagnostics for Oncology
Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Middle
East and Africa Companion Diagnostics for Oncology Market Revenue (US$ Mn)
15.2. Middle
East and Africa Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Offering
15.2.1. Assay
Kits and Reagents
15.2.2. Software
15.2.3. Services
15.3. Middle
East and Africa Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Technology
15.3.1. In Situ
Hybridization (ISH)
15.3.2. Polymerase
Chain Reaction (PCR)
15.3.3. Immunohistochemistry
(IHC)
15.3.4. Next-Generation
Sequencing (NGS)
15.3.5. Others
15.4. Middle
East and Africa Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts,
By Disease Indication
15.4.1. Breast
Cancer
15.4.2. Ovarian
Cancer
15.4.3. Colorectal
cancer
15.4.4. Non-small
Cell Lung Cancer
15.4.5. Blood
Cancer
15.4.6. Others
15.5. Middle
East and Africa Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By End Users
15.5.1. Hospitals
15.5.2. Diagnostics
Laboratories
15.5.3. Others
15.6. Middle
East and Africa Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Offering
15.6.1.1.1. Assay Kits and Reagents
15.6.1.1.2. Software
15.6.1.1.3. Services
15.6.1.2. Saudi Arabia Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Technology
15.6.1.2.1. In Situ Hybridization (ISH)
15.6.1.2.2. Polymerase Chain Reaction (PCR)
15.6.1.2.3. Immunohistochemistry (IHC)
15.6.1.2.4. Next-Generation Sequencing (NGS)
15.6.1.2.5. Others
15.6.1.3. Saudi Arabia Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
15.6.1.3.1. Breast Cancer
15.6.1.3.2. Ovarian Cancer
15.6.1.3.3. Colorectal cancer
15.6.1.3.4. Non-small Cell Lung Cancer
15.6.1.3.5. Blood Cancer
15.6.1.3.6. Others
15.6.1.4. Saudi Arabia Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By End Users
15.6.1.4.1. Hospitals
15.6.1.4.2. Diagnostics Laboratories
15.6.1.4.3. Others
15.6.2. UAE
15.6.2.1. UAE Companion Diagnostics for Oncology Market Revenue (US$ Mn)
and Forecasts, By Offering
15.6.2.1.1. Assay Kits and Reagents
15.6.2.1.2. Software
15.6.2.1.3. Services
15.6.2.2. UAE Companion Diagnostics for Oncology Market Revenue (US$ Mn)
and Forecasts, By Technology
15.6.2.2.1. In Situ Hybridization (ISH)
15.6.2.2.2. Polymerase Chain Reaction (PCR)
15.6.2.2.3. Immunohistochemistry (IHC)
15.6.2.2.4. Next-Generation Sequencing (NGS)
15.6.2.2.5. Others
15.6.2.3. UAE Companion Diagnostics for Oncology Market Revenue (US$ Mn)
and Forecasts, By Disease Indication
15.6.2.3.1. Breast Cancer
15.6.2.3.2. Ovarian Cancer
15.6.2.3.3. Colorectal cancer
15.6.2.3.4. Non-small Cell Lung Cancer
15.6.2.3.5. Blood Cancer
15.6.2.3.6. Others
15.6.2.4. UAE Companion Diagnostics for Oncology Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.2.4.1. Hospitals
15.6.2.4.2. Diagnostics Laboratories
15.6.2.4.3. Others
15.6.3. Egypt
15.6.3.1. Egypt Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
15.6.3.1.1. Assay Kits and Reagents
15.6.3.1.2. Software
15.6.3.1.3. Services
15.6.3.2. Egypt Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
15.6.3.2.1. In Situ Hybridization (ISH)
15.6.3.2.2. Polymerase Chain Reaction (PCR)
15.6.3.2.3. Immunohistochemistry (IHC)
15.6.3.2.4. Next-Generation Sequencing (NGS)
15.6.3.2.5. Others
15.6.3.3. Egypt Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
15.6.3.3.1. Breast Cancer
15.6.3.3.2. Ovarian Cancer
15.6.3.3.3. Colorectal cancer
15.6.3.3.4. Non-small Cell Lung Cancer
15.6.3.3.5. Blood Cancer
15.6.3.3.6. Others
15.6.3.4. Egypt Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
15.6.3.4.1. Hospitals
15.6.3.4.2. Diagnostics Laboratories
15.6.3.4.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
15.6.4.1.1. Assay Kits and Reagents
15.6.4.1.2. Software
15.6.4.1.3. Services
15.6.4.2. Kuwait Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
15.6.4.2.1. In Situ Hybridization (ISH)
15.6.4.2.2. Polymerase Chain Reaction (PCR)
15.6.4.2.3. Immunohistochemistry (IHC)
15.6.4.2.4. Next-Generation Sequencing (NGS)
15.6.4.2.5. Others
15.6.4.3. Kuwait Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
15.6.4.3.1. Breast Cancer
15.6.4.3.2. Ovarian Cancer
15.6.4.3.3. Colorectal cancer
15.6.4.3.4. Non-small Cell Lung Cancer
15.6.4.3.5. Blood Cancer
15.6.4.3.6. Others
15.6.4.4. Kuwait Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
15.6.4.4.1. Hospitals
15.6.4.4.2. Diagnostics Laboratories
15.6.4.4.3. Others
15.6.5. South
Africa
15.6.5.1. South Africa Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Offering
15.6.5.1.1. Assay Kits and Reagents
15.6.5.1.2. Software
15.6.5.1.3. Services
15.6.5.2. South Africa Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Technology
15.6.5.2.1. In Situ Hybridization (ISH)
15.6.5.2.2. Polymerase Chain Reaction (PCR)
15.6.5.2.3. Immunohistochemistry (IHC)
15.6.5.2.4. Next-Generation Sequencing (NGS)
15.6.5.2.5. Others
15.6.5.3. South Africa Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
15.6.5.3.1. Breast Cancer
15.6.5.3.2. Ovarian Cancer
15.6.5.3.3. Colorectal cancer
15.6.5.3.4. Non-small Cell Lung Cancer
15.6.5.3.5. Blood Cancer
15.6.5.3.6. Others
15.6.5.4. South Africa Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By End Users
15.6.5.4.1. Hospitals
15.6.5.4.2. Diagnostics Laboratories
15.6.5.4.3. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Companion Diagnostics for
Oncology Market Revenue (US$ Mn) and Forecasts, By Offering
15.6.6.1.1. Assay Kits and Reagents
15.6.6.1.2. Software
15.6.6.1.3. Services
15.6.6.2. Rest of Middle East & Africa Companion Diagnostics for
Oncology Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.6.2.1. In Situ Hybridization (ISH)
15.6.6.2.2. Polymerase Chain Reaction (PCR)
15.6.6.2.3. Immunohistochemistry (IHC)
15.6.6.2.4. Next-Generation Sequencing (NGS)
15.6.6.2.5. Others
15.6.6.3. Rest of Middle East & Africa Companion Diagnostics for
Oncology Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.6.6.3.1. Breast Cancer
15.6.6.3.2. Ovarian Cancer
15.6.6.3.3. Colorectal cancer
15.6.6.3.4. Non-small Cell Lung Cancer
15.6.6.3.5. Blood Cancer
15.6.6.3.6. Others
15.6.6.4. Rest of Middle East & Africa Companion Diagnostics for
Oncology Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1. Hospitals
15.6.6.4.2. Diagnostics Laboratories
15.6.6.4.3. Others
15.7. Key Segment
for Channeling Investments
15.7.1. By
Country
15.7.2. By
Offering
15.7.3. By
Technology
15.7.4. By
Disease Indication
15.7.5. By End
Users
16. Latin America Companion Diagnostics for Oncology Market
Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Latin
America Companion Diagnostics for Oncology Market Revenue (US$ Mn)
16.2. Latin
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Offering
16.2.1. Assay
Kits and Reagents
16.2.2. Software
16.2.3. Services
16.3. Latin
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Technology
16.3.1. In Situ
Hybridization (ISH)
16.3.2. Polymerase
Chain Reaction (PCR)
16.3.3. Immunohistochemistry
(IHC)
16.3.4. Next-Generation
Sequencing (NGS)
16.3.5. Others
16.4. Latin
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
16.4.1. Breast
Cancer
16.4.2. Ovarian
Cancer
16.4.3. Colorectal
cancer
16.4.4. Non-small
Cell Lung Cancer
16.4.5. Blood
Cancer
16.4.6. Others
16.5. Latin
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and Forecasts,
By End Users
16.5.1. Hospitals
16.5.2. Diagnostics
Laboratories
16.5.3. Others
16.6. Latin
America Companion Diagnostics for Oncology Market Revenue (US$ Mn) and
Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Offering
16.6.1.1.1. Assay Kits and Reagents
16.6.1.1.2. Software
16.6.1.1.3. Services
16.6.1.2. Brazil Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Technology
16.6.1.2.1. In Situ Hybridization (ISH)
16.6.1.2.2. Polymerase Chain Reaction (PCR)
16.6.1.2.3. Immunohistochemistry (IHC)
16.6.1.2.4. Next-Generation Sequencing (NGS)
16.6.1.2.5. Others
16.6.1.3. Brazil Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By Disease Indication
16.6.1.3.1. Breast Cancer
16.6.1.3.2. Ovarian Cancer
16.6.1.3.3. Colorectal cancer
16.6.1.3.4. Non-small Cell Lung Cancer
16.6.1.3.5. Blood Cancer
16.6.1.3.6. Others
16.6.1.4. Brazil Companion Diagnostics for Oncology Market Revenue (US$
Mn) and Forecasts, By End Users
16.6.1.4.1. Hospitals
16.6.1.4.2. Diagnostics Laboratories
16.6.1.4.3. Others
16.6.2. Argentina
16.6.2.1. Argentina Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Offering
16.6.2.1.1. Assay Kits and Reagents
16.6.2.1.2. Software
16.6.2.1.3. Services
16.6.2.2. Argentina Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Technology
16.6.2.2.1. In Situ Hybridization (ISH)
16.6.2.2.2. Polymerase Chain Reaction (PCR)
16.6.2.2.3. Immunohistochemistry (IHC)
16.6.2.2.4. Next-Generation Sequencing (NGS)
16.6.2.2.5. Others
16.6.2.3. Argentina Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
16.6.2.3.1. Breast Cancer
16.6.2.3.2. Ovarian Cancer
16.6.2.3.3. Colorectal cancer
16.6.2.3.4. Non-small Cell Lung Cancer
16.6.2.3.5. Blood Cancer
16.6.2.3.6. Others
16.6.2.4. Argentina Companion Diagnostics for Oncology Market Revenue
(US$ Mn) and Forecasts, By End Users
16.6.2.4.1. Hospitals
16.6.2.4.2. Diagnostics Laboratories
16.6.2.4.3. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Companion Diagnostics for Oncology
Market Revenue (US$ Mn) and Forecasts, By Offering
16.6.3.1.1. Assay Kits and Reagents
16.6.3.1.2. Software
16.6.3.1.3. Services
16.6.3.2. Rest of Latin America Companion Diagnostics for Oncology
Market Revenue (US$ Mn) and Forecasts, By Technology
16.6.3.2.1. In Situ Hybridization (ISH)
16.6.3.2.2. Polymerase Chain Reaction (PCR)
16.6.3.2.3. Immunohistochemistry (IHC)
16.6.3.2.4. Next-Generation Sequencing (NGS)
16.6.3.2.5. Others
16.6.3.3. Rest of Latin America Companion Diagnostics for Oncology
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
16.6.3.3.1. Breast Cancer
16.6.3.3.2. Ovarian Cancer
16.6.3.3.3. Colorectal cancer
16.6.3.3.4. Non-small Cell Lung Cancer
16.6.3.3.5. Blood Cancer
16.6.3.3.6. Others
16.6.3.4. Rest of Latin America Companion Diagnostics for Oncology
Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.4.1. Hospitals
16.6.3.4.2. Diagnostics Laboratories
16.6.3.4.3. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Offering
16.7.3. By
Technology
16.7.4. By
Disease Indication
16.7.5. By End Users
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2020
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. Abbott
Laboratories
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Amgen
Inc.
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business Strategies
18.3. ARUP Laboratories, Inc.
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business Strategies
18.4. AstraZeneca
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business Strategies
18.5. bioMérieux Inc.
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business Strategies
18.6. F. Hoffmann-La Roche Ltd
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business Strategies
18.7. FOUNDATION MEDICINE, INC.
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business Strategies
18.8. Guardant Health, Inc.
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business Strategies
18.9. ICON plc
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business Strategies
18.10. Illumina, Inc.
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business Strategies
18.11. Invivoscribe Technologies, Inc.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business Strategies
18.12. Leica Biosystems
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business Strategies
18.13. Myriad Genetics, Inc.
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business Strategies
18.14. Pillar Biosciences, Inc.
18.14.1. Company
Details
18.14.2. Company
Overview
18.14.3. Product
Offerings
18.14.4. Key
Developments
18.14.5. Financial
Analysis
18.14.6. SWOT
Analysis
18.14.7. Business Strategies
18.15. Resonance Health Analysis
Services Pty Ltd
18.15.1. Company
Details
18.15.2. Company
Overview
18.15.3. Product
Offerings
18.15.4. Key
Developments
18.15.5. Financial
Analysis
18.15.6. SWOT
Analysis
18.15.7. Business Strategies
18.16. Thermo Fisher Scientific Inc.
18.16.1. Company
Details
18.16.2. Company
Overview
18.16.3. Product
Offerings
18.16.4. Key
Developments
18.16.5. Financial
Analysis
18.16.6. SWOT
Analysis
18.16.7. Business Strategies
18.17. Other Market Participants
19. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.